Fig. 4From: Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotateSurvival (percentage) after 213Bi-DOTATATE or DOTATATE treatment in a H69 tumour-bearing and b CA20948 tumour-bearing miceBack to article page